Skip to main content

Table 3 Cox regression analysis for breast cancer death for patients with gene expression data (n = 69 to 77)

From: TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer

 

Univariate analysis

Multivariate analysis

 

RR

95 percent CI

P

RR

95 percent CI

P

Age, ≥55 years versus <55 years

1.22

0.52–2.84

0.65

   

Tumor type (overall effect)

  

0.32

   

   Lobular (versus ductal)

0.65

0.28–1.51

0.31

   

   Other (versus ductal)

0.34

0.05–2.53

0.29

   

Tumor size (overall effect)

  

0.014

   

   pT2 (versus pT1)

2.63

0.88–7.86

0.085

   

   pT3–pT4 (versus pT1)

5.27

1.61–17.2

0.006

   

Lymph node status (overall effect)

  

0.016

  

0.004

   pN1 (versus pN0)

0.45

0.16–1.26

0.13

0.47

0.17–1.33

0.15

   pN2–pN3 (versus pN0)

2.41

0.95–6.08

0.064

3.42

1.29–9.05

0.013

   Othera (versus pN0)

2.12

0.75–5.98

0.16

2.70

0.93–7.78

0.067

Histological grade (overall effect)

  

0.68

   

   G2 (versus G1)

2.20

0.30–16.3

0.44

   

   G3 (versus G1)

2.07

0.25–16.8

0.50

   

TP53 mutation (versus wild type)

3.46

1.66–7.21

0.002

4.43

2.04–9.64

0.0004

ER positive (versus negative)

0.75

0.35–1.63

0.48

   

PR positive (versus negative)

0.71

0.33–1.51

0.38

   

Gene expression (overall effect)

  

0.006

   

   Highly proliferating luminal (versus luminal A)

6.59

1.79–24.3

0.005

   

   Normal like (versus luminal A)

2.82

0.71–11.3

0.14

   

   Basal like (versus luminal A)

6.93

1.79–26.8

0.005

   

   ERRB2+ (versus luminal A)

5.82

1.30–26.2

0.022

   
  1. aLymph nodes not removed. 95 percent CI, 95 percent confidence interval for relative risk; ER, estrogen receptor; PR, progesterone receptor; P, P value for the hypothesis of no effect; RR, relative risk (hazard ratio).